Publications by authors named "Mona Vashi"
Article Synopsis
- Researchers are investigating the effectiveness of alpha-2 adrenergic receptor (α AR) agonists, like dexmedetomidine (DEX), in reducing COVID-19 mortality by targeting hyperinflammation and respiratory issues.
- A study analyzed 214 adults requiring mechanical ventilation and found that 28-day mortality was significantly lower (27%) in those who received DEX compared to those who did not (64.5%), indicating a relative risk reduction of 58.2%.
- Early administration of DEX, within 3.4 days after intubation, was particularly effective in reducing mortality, suggesting that further randomized controlled trials are necessary to validate these findings.
Background: Pulmonary endothelial cells' (ECs) injury and apoptotic death are necessary and sufficient for the pathogenesis of the acute respiratory distress syndrome (ARDS), regardless of epithelial damage. Interaction of dysfunctional ECs with circulatory extracellular vesicles (EVs) holds therapeutic promise in ARDS. However, the presence in the blood of long-term ARDS survivors of EVs with a distinct phenotype compared to the EVs of non-surviving patients is not reported.
View Article and Find Full Text PDF